52North, a Cambridge, UK-based med-tech firm centered on pressing care pathways in oncology, raised £4.72M in funding.
The spherical was led by KHP Ventures, and Cedars-Sinai Mental Property Co., with participation from OKG Capital, Cambridge Enterprise Ventures, Most cancers Analysis Horizons, Macmillan Most cancers Assist, and chosen angels together with biotech entrepreneur Jonathan Milner and former CEO of Roche Diagnostics Roland Diggelmann.
The corporate intends to make use of the funds to advance its merchandise in direction of market, together with the flagship Neutrocheck®, which was granted breakthrough standing by the UK Authorities underneath its pilot Modern Units Entry Pathwayearlier this yr.
Based in 2018 by a workforce of College of Cambridge postgraduates, 52North makes a speciality of oncology-focused med-tech, offering low-cost merchandise to streamline pressing care pathways and improve affected person security throughout all socio-economic teams.
The above merchandise are nonetheless in improvement, haven’t been authorised by regulators and are usually not presently accessible on the market.
FinSMEs
06/12/2024
